Therapeutic Orientation Test in Thrombotic Microangiopathy (TOTEM)

July 18, 2025 updated by: University Hospital, Montpellier

Haemolytic and Uraemic Syndrome (HUS) is a serious disease requiring rapid diagnosis and management. The atypical HUS diagnosis has been greatly improved by anti-CS antibody (Eculizumab) wich block alternative complement pathway activation. To rise treatment success, Eculizumab introduction should be as early as possible. In some secondary HUS (infection, drugs…) complement is also involved as "second-hit".

To date, there is no tool to confirm complement involvement in a HUS at diagnosis stage. This study suggest to evaluate a therapeutic orientation test, in order to determine the complement implication in HUS diagnosis. The test evaluates the complement deposits on endothelial cell surface in vitro, compared to a normal human serum.

In order to determine the test performance, first the positive or negative results will be compared to the HUS clinical evolution, treated or not by the clinician with Eculizumab. Second, the test results will be compared to the presence of alternative complement pathway regulation abnormalities.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Recruiting

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Estimated)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
100

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact

The name and contact information for the person who can answer enrollment questions for a clinical study. Each location where the study is being conducted may also have a specific contact, who may be better able to answer those questions.

Study Locations

  • France
      • Bordeaux, France
        • Recruiting
        • CHU de Bordeaux
        • Contact:
          • COUZI Lionel, MD
        • Principal Investigator:
          • COUZI Lionel, MD
        • Principal Investigator:
          • HARAMBAT Jérôme, MD
        • Sub-Investigator:
          • DELMAS Muriel-Yahsou, MD
      • Cabestany, France
        • Not yet recruiting
        • Site Médipôle Cabestany
        • Contact:
          • DECOURT Alexandre, MD
        • Principal Investigator:
          • DECOURT Alexandre, MD
      • Castelnau-le-Lez, France
        • Not yet recruiting
        • Centre Nephrocare Castelnau-le-Lez
        • Contact:
          • JUGANT Sébastien, MD
        • Principal Investigator:
          • JUGANT Sébastien, MD
      • Grenoble, France
        • Recruiting
        • CHU de Grenoble
        • Contact:
          • ROSTAING Lionel, MD
        • Principal Investigator:
          • ROSTAING Lionel, MD
        • Sub-Investigator:
          • JOUVE Thomas, MD
      • Lille, France
        • Recruiting
        • CHU de Lille
        • Contact:
          • PROVOT François, MD
        • Principal Investigator:
          • PROVOT François, MD
        • Principal Investigator:
          • NOVO Robert, MD
      • Limoges, France
        • Recruiting
        • CHU de Limoges
        • Principal Investigator:
          • GUIGONIS Vincent, MD
        • Contact:
          • MUGNIER Clovis, MD
        • Principal Investigator:
          • MUGNIER Clovis, MD
        • Sub-Investigator:
          • DANTHU Clement, MD
      • Marseille, France
        • Recruiting
        • APHM-Hôpital de la Conception
        • Contact:
          • JOURDE-CHICHE Noémie, MD
        • Principal Investigator:
          • JOURDE-CHICHE Noémie, MD
        • Sub-Investigator:
          • SALLEE Marion, MD
      • Montpellier, France
        • Recruiting
        • Montpellier University Hospital
        • Contact:
          • Moglie LE QUINTREC-DONNETTE, Pr
      • Nantes, France
        • Recruiting
        • CHU de Nantes
        • Contact:
          • VILLE Simon, MD
        • Principal Investigator:
          • ROUSSEY Gwenaelle
        • Principal Investigator:
          • VILLE Simon
      • Narbonne, France
        • Not yet recruiting
        • HPGN- Narbonne
        • Contact:
          • COLDEFY Olivier, MD
        • Principal Investigator:
          • COLDEFY Olivier, MD
      • Nice, France
        • Recruiting
        • Chu de Nice
        • Contact:
          • ESNAULT Vincent, MD
        • Principal Investigator:
          • ESNAULT Vincent, MD
        • Sub-Investigator:
          • SICARD Antoine, MD
        • Sub-Investigator:
          • GOSSET Clément, MS
      • Nîmes, France
        • Recruiting
        • CHU de Nîmes
        • Contact:
          • MORANNE Olivier, MD
        • Principal Investigator:
          • MORANNE Olivier, MD
      • Paris, France
        • Recruiting
        • Hôpital Paris Necker
        • Contact:
          • SERVAIS Aude, MD
        • Principal Investigator:
          • SERVAIS Aude, MD
        • Principal Investigator:
          • BOYER Olivia, MD
        • Sub-Investigator:
          • ZUBER Julien, MD
      • Paris, France
        • Recruiting
        • APHP-Hôpital Tenon
        • Contact:
          • MESNARD Laurent, MD
        • Principal Investigator:
          • MESNARD Laurent, MD
        • Sub-Investigator:
          • RAFAT Cédric, MD
      • Perpignan, France
        • Recruiting
        • CH de Perpignan
        • Contact:
          • CANET Sébastien, MD
        • Principal Investigator:
          • CANET Sébastien, MD
      • Poitiers, France
        • Recruiting
        • CHU De Poitiers
        • Contact:
          • BRIDOUX Frank, MD
        • Principal Investigator:
          • BRIDOUX Frank, MD
        • Sub-Investigator:
          • THIERRY Antoine, MD
      • Rouen, France
        • Recruiting
        • CHU de ROUEN
        • Contact:
          • GUERROT Dominique, MD
        • Principal Investigator:
          • GUERROT Dominique, MD
        • Principal Investigator:
          • GRANGE Steven, MD
      • Strasbourg, France
        • Recruiting
        • Hopitaux universitaires de Strasbourg
        • Contact:
          • CAILLARD OHLMANN Sophie, MD
        • Principal Investigator:
          • CAILLARD OHLMANN Sophie, MD
      • Toulouse, France
        • Recruiting
        • CHU de Toulouse
        • Contact:
          • RIBES David, MD
        • Principal Investigator:
          • DECRAMER Stéphane, MD
        • Principal Investigator:
          • RIBES David, MD
        • Sub-Investigator:
          • FAGUER Stanislas, MD
      • Tours, France
        • Recruiting
        • CHRU Tours
        • Contact:
          • HALIMI Jean-Michel, MD
        • Principal Investigator:
          • HALIMI Jean-Michel, MD

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

No older than 90 years (Child, Adult, Older Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

TMA with:

  • mechanic haemolytic anemia, undetectable haptoglobin, LDH>1.5*LNS
  • thrombopenia
  • acute kidney injury TMA on native kidney or in post-transplantation.

Exclusion Criteria:

  • DIVC patients
  • plasma exchange during 1 month before sample collection
  • treatment by Eculizumab before sample collection
  • no consent
  • not beneficiary of a social security
  • pregnancy or breastfeeding
  • patient Under guardianship

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Diagnostic
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Experimental: Patients with Thrombotic micro-angiopathy
Diagnostic test: Therapeutic orientation test for TMA
Therapeutic orientation test for TMA performed on blood sample at inclusion, first visit at 1 month and last visit at 6 months.

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Therapeutic orientation test sensitivity
Time Frame: Through study completion, an average of 3 years.
The proportion of patients testing positive among those receiving a relevant Eculizumab treatment ( TMA resolution with treatment or presence of abnormalities in alternative complement pathway.
Through study completion, an average of 3 years.
Therapeutic orientation test specificity
Time Frame: Through study completion, an average of 3 years.
The proportion of patients testing negative among patients who did not receive Eculizumab treatment.(TMA resolution without treatment or therapeutic failure with Eculizumab).
Through study completion, an average of 3 years.

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Untreated test positive patients
Time Frame: Through study completion, an average of 3 years.
The proportion of patients with positive test but untreated by Eculizumab, and who therefore could have benefited from treatment.
Through study completion, an average of 3 years.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
University Hospital, Montpellier

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
April 3, 2021

Primary Completion (Estimated)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
October 3, 2026

Study Completion (Estimated)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
April 3, 2027

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
February 19, 2021

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
February 25, 2021

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
March 2, 2021

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
July 23, 2025

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
July 18, 2025

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
July 1, 2025

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • RECHMPL19_0075

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Thrombotic Micro-angiopathy

Clinical Trials on Therapeutic orientation test for TMA

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings